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INTRODUCTION
Chronic obstructive pulmonary disease is the most common lung
disease and major causes of disability and death in the world population.
WHO estimates that by 2000, 2.74 million copd people died, world wide.
Copd is the most common disorder, affiliating 10-15% of adults
over the age of 40 Yrs and prevalence is increasing.
According to American thoracic society 1952, chronic bronchitis is
defined as chronic cough, expectoration for at least for 3 months for 2
consecutive  years.   Most  common  causes  are  cigarette  smoking  (Vs
surgeon general,  1984),  air  pollution,  frequent  bronchial  infection  and
certain occupation.
Institution based pulmonary rehabilitation programs incorporating
the airway clearance technique have shown to improve HRQL (Health
related quality of life), reduces dyspnoea and improve exercise tolerance.
Mechanical  device  such  as  the  flutter  valves  is  able  to  provide  the
benefits of improved airway clearance in COPD patients.
Flutter a positive expiratory pressure technique eliminates mucus
from  the  bronchial  airway  and  thus  improves  bronchial  hygiene  in
chronic bronchitis patients.
By  using  flutter  device  there  was  a  statistically  significant
improvement in FEV1 and FVC, whether patients were pretreated with
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mucus  clearance  device  there  was  a  significant  improvement  in  lung
function compared to baseline with combined bronchodilator therapy.
Therefore the present study is intended to analyze the effectiveness
of flutter device on lung function in copd subjects with retained secretion.
AIM OF STUDY
The  aim  of  the  study  is  to  analyze  the  effectiveness  of  flutter
mucous clearance device on lung function in copd subjects with retained
secretion.
OBJECTIVES OF THE STUDY
• To study the effectiveness of flutter device on mucous clearance in
copd subjects and retained secretion.
• To study the effectiveness of lung function in copd with retained
secretion.
HYPOTHESIS
Null Hypothesis
There will be no significant difference between pre and post test
value of  flutter  device  on mucus  clearance  and lung function in  copd
subjects with retained secretion. 
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Alternate Hypothesis
There will be significant difference between pre and post test value
of flutter device on mucus clearance and lung function in copd subjects
with retained secretion. 
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REVIEWS OF LITERATURE
NORMAN WOLKOVE et al., (2010)
Conducted this study with 23 copd patients, to determine the use of
mucus  clearance  device  (MCD)  could  improve  the  bronchodilator
response  delivered  by  a  metered  –  dose  inhaler.   And  concluded
immediately  after  the use of  MCD there was a statistically significant
improvenment in FEV1, and FVC. 
ANGSHU BROWMIKA et al., (2008)
Conducted  a  study  in  patients  with  copd  experience  mucus
hypersecretion.  This review examines the current evidence base and best
clinical practise in the area of airway clearance. Mechanical device such
as flutter valves, positive end expiratory pressure, high frequency chest
wall oscillation may be able to provide the benefits of improved airway
clearance.
CHIEN LING SU et al., (2007)
A Prospective,  randomized,  controlled study of  32 patients  with
COPD. They have been divided into 2 groups, of either PEP+FET(n=16)
or FET alone(n=16) for 4 weeks.  Finally the result shows, at the end of 4
weeks  intervention  PEP  +  FET  had  shows  significant  increase  in
diffusing capacity (DLCO).PEP therapy as an adjunct to FET .
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L.C.de LIMAA et al., (2004)
Conducted  this  study  to  show  the  mechanical  behavior  of  the
flutter VRP1, a respiratory physiotherapy device designed to aid sputum
clearance  and  showed  information  that  could  be  beneficial  to  the
professional of the respiratory physiotherapy.
HRISTARA – PAPADOPOULON et al., (2003)
Conduced a study to show the effectiveness of current devices of
respiratory  physiotheraphy,  like   PEP,  High  frequency  chest  wall
oscillation,  oral  high  frequency  oscillation,  Incentive  spirometer,  the
flutter and the cornet, and concluded these devices, help the removal of
mucus from the airways and improvement of pulmonary function.
SHARON M.H. et al., (2003)
Conducted  a  randomized  study  with  15  bronchiectasis  patients,
divided into 3 groups:  postural  drainage and breathing and coughing;
flutter  valve   +  Breathing  and  coughing;  Breathing  coughing  along,
applied for 15 minutes daily in all groups and concluded flutter device
was perceived as being the most effective in clearing secretion.
ANDREA BELLONE et al., (2000)
Conducted a study to compare the short-term effects  of postural
drainage,  oscillating  positive  expiratory  pressure  (using  flutter  device)
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and expiration with the glottis open in the lateral posture (ELTGOL) with
10 chronic bronchitis patients, at the end of the treatment,  concluded that
FLUTTER and ELTGOL techniques were more effective in prolonging
secretion removal in chronic bronchitis.
ANNE E HOLLANDI et al., (2000)
A clinical trials of airway clearance techniques (ACTS) in COPD
have shown a physiological   rationale for  the use of  ACTS in COPD.
Positive Expiratory pressure theraphy or autogenic drainage may prove
effective in COPD Patients.
SKARIA SMIBI et al., (1998) 
Conducted a randomized controlled study by, comparing the effect
of positive pressure technique using flutter device, over forced expiratory
pressure  technique,  with  30  chronic  bronchitis  patients  divided  into  2
groups (Group A and Group B) each of 2 session per day for 15 minutes
for 5 days weekly for totally 2 weeks and concluded at the end of 2nd
week,  significant  improvement  in  bronchial  hygiene  was  found  with
independent ‘t’ test at in Group-A when compared with Group – B.
LANGENDERFER et al., (1998)
Conducted  the  studies  on  the  efficacy  of  old  and  new  mucus
clearance  techniques  and  the  recommendation  for  different  patients.
Percussion  and  postural  drainage  was  the  traditional  method  of
facilitating mucus clearance, but  the hazards and contraindication along
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with  poor  patient  complaints  led  to  the  development  of   alternative
therapy  like  autogenic  drainage,  PEP,  flutter  valve  therapy  and  high-
frequency cheast compression.  These alternatives depends on the ability,
motivations, preference, and resource of each patient.
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MATERIALS AND METHODOLOGY
MATERIALS
 Personal data
 Flutter device
 Stethoscope
 Computerized Spirometer
 Sputum box
METHODOLOGY
Study Design
Quasi experimenta study
Study Setting
The  study  was  conducted  at  the  outpatient  department  in
JKKMMRF  College  of  physiotherapy,  and  District  Head  Quarters
Hospital, Erode, under the supervision of concerned authority.
Study sampling
A total of 30 subject were selected by purposive random sampling
method after  due consideration to the inclusion and exclusion criteria.
They were divided into Group A and Group B, with 15 subjects in each
group.
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STUDY DURATION 
Duration of study : 1 Month 
Group A: Flutter Device by the session of 5 to 15 perday along with
general medication
Group B : Chest physiotherapy for 5 to 15 minutes along with general
medication. 
INCLUSION CRITERIA
• Sex : Both
• Age : 40 – 60
• Stable clinical subject
• Chronic bronchitis (COPD)
• Smokers
• History of copd for past 2 years
EXCLUSION CRITERIA
• Pneumothorax
• Overt right sided heart failure
• Severe  heart,  Renal,  Liver,  Blood system and endocrine  system
dysfunction
• Active hemoptysis
• Acute coronary syndrome
PARAMETERS
Pulmonary Function Test
• Force vital capacity (FVC)
• Forced Expiratory volume in one second (FEV1)
FIG:1- COMPUTERSIZED SPIROMETER
9
FIG:1- ASSESSORY
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PARAMETER DESCRIPTION
Computerization of pulmonary function testing is forcing rewrites
of time – honored protocols and shifting responsibilities from technician
to  machine.   Pulmonary  function  testing  measures  how  well  we  are
breathing.  Spirometry is a simple test to measure how much (volume)
and how fast  (flow) you can move air  into and out of our lungs,  and
provide visual and auditory feed back as the patient breaths.
FVC (FORCED VITAL CAPACITY)
The Maximum volume of  air  forcibly expired  after  a maximum
inspiration. It consist of tidal volume + inspiratory and Expiratory reserve
volume.  Normal value of FVC is 4.7 to 5 liters.
FEV1 (FORCED EXPIRATORY VOLUME PER SECOND)
The Volume of air forcibly expired after a maximum inspiration in
one second.  Normal value of FEV1 is 4.3 – 4.6 liters. 
PROCEDURE
¾ 30 Subjects were selected by convenient sampling method with due
consideration  of  inclusion  and  exclusion  criterias,  each  group
consist  of 15 subjects.
¾ Experimental  group-A  were given general  medicine  along with
flutter device 
¾ Control group-B subjects were given general medicine with chest
physiotherapy.
¾ Pre test  values  were obtained for  both experimental  and control
group.
¾ After the intervention the post test values were obtained for both
experimental and control group.
¾ The  pre  and  post  test  mean  values  of  both  the  groups  were
compared.   
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FIG:2- COMPUTERSIZED SPIROMETER WITH PATIENT
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STATISTICAL TOOLS
The collected data was subjected to statistical analysis using paired
and unpaired ‘t' test to find out the research effectiveness.
Paired “t” Test
The  paired  “t”  test  will  be  used  to  find  out  the  statistical
significance between pre and post test values of flutter device by using
lung function in Group A and B subjects.
Formula: Paired t-test
S = 
1
)( 22
−
− ∑∑
n
n
d
d
t =
S
nd
d = Difference between the Pre Test Vs Post Test
d = Mean difference
n = Total number of subjects
S = Standard deviation
 Unpaired T-Test :
The unpaired t-test was used to compare the statistically significant
difference between Group A and B subjects treated with flutter device by
using Lung function test.
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2
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n1 = Total number of subject in Group - A
n2 = Total number of subject in Group – B
x1 = Difference between Pre test Vs post test of Group - A
1x = Mean Difference between Pre test Vs post test of Group – A
x2 = Difference between Pre test Vs post test of Group – B
2x = Mean Difference between Pre test Vs post test of Group – B
S = Standard deviation
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DATA   PRESENTATION
TABLE – 1
Sl.No.
FVC in liters FEV1 in liters
Group – A Group – B Group – A Group – B
Pre Post Pre Post Pre Post Pre Post
1. 3.2 3.3 2.1 2.12 3.2 3.8 3.0 3.2
2. 2.30 2.41 1.52 2.18 2.30 2.41 2.13 2.17
3. 4.54 4.63 3.12 3.16 4.54 4.58 4.29 4.50
4. 2.8 2.64 3.02 3.17 2.8 2.12 3.9 3.50
5. 4.97 5.10 2.0 2.22 4.97 5.4 2.89 3.10
6. 2.29 3.06 2.07 3.12 2.29 2.44 2.18 3.2
7. 2.04 2.06 2.15 2.33 2.04 2.12 1.18 1.29
8. 2.45 2.49 2.04 2.18 2.45 2.58 2.40 2.43
9. 3.77 3.78 2.15 3.93 3.77 3.82 3.70 3.88
10. 3.85 3.93 2.47 3.52 3.85 3.98 3.80 3.88
11. 3.57 3.64 2.15 2.42 3.57 3.78 3.58 3.65
12. 2.92 3.94 3.08 3.12 2.92 2.98 2.88 3.91
13. 2.33 2.52 3.11 3.21 2.33 2.47 2.02 2.17
14. 2.08 2.12 2.07 2.14 2.08 3.02 2.08 2.15
15. 1.12 1.49 2.33 2.47 1.12 1.49 1.07 1.17
FVC- Forced Vital Capacity
FEV1 – Forced Expiration Volume in 1 Second
DATA ANALYSIS & INTERPRETATION
TABLE II
FVC 
in Liters
Mean Mean
Diff.
SD Paired
T value
Pre Test 2.94
0.2 0.08 10.15
Post test 3.14
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The paired “t” value 10.15   was greater than that of the tabulated
value 2.15,  which showed a significant  difference at  0.05 the level  of
between pre & post test result.  The pre test mean was 2.94 & post test
mean was 3.14   with a mean difference of 0.2. This showed a significant
difference in  FVC level  between  pre  & post  scores  in  experimental
group.
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TABLE III
FVC 
in Liters
Mean Mean Diff. SD
Paired ‘t’
Value
Pre Test 2.35 0.4 0.19 8.96Post test 2.75
The paired ‘t’  value  8.96  greater than that of the tabulated ‘t’
value 2.15  which showed no significant difference at 0.05 level between
pre vs. post test result.  The pre test mean was   2.35   & post test mean
2.75    with  mean  difference  only   0.4.   This  showed  no significant
difference in FVC level between pre & post level of control group.
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TABLE IV
FVC
in Liters
Mean Mean
Diff.
SD Unpaired
T – value
Post Test
(Experimental group)
3.14
0.39 0.13 7.95Post test
(Control Group)
2.75
The unpaired ‘t’ value  7.95    was greater than that of the tabulated
value 2.05 which showed a significant  difference at the level of  0.05
between post FVC of control & experimental group.
The  post  test  mean  of  control  group  being  2.75  &  that  of
experimental  group  being  3.14  with  mean  difference  of  0.39.  This
showed  a  significant  difference  in  FVC level  between  post  test  score
between control & experimental group.
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TABLE V
FEV1
Liters / Sec
Mean
Mean
Diff.
SD
Paired
T – value
Pre Test 2.94 0.19 0.08 13.06Post test 3.13
The paired ‘t’ value  13.06  was greater than that of the tabulated 
value   2.15   which showed significant difference at 0.05  level between
pre vs. post test result.  The pre test mean was   2.94  & post test mean
was  3.13  with  mean  difference  of   0.19.  This  showed significant
difference in  FEV1  level  between  pre  &  post  level  in  experimental
group.
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TABLE VI
FEV1 Liters / Sec Mean
Mean
Diff.
SD
Paired
T – value
Pre Test 2.74 0.2 0.10 10.06Post test 2.94
The paired ‘t’ value   10.06  was greater than that of the tabulated
‘t’  value   2.15   which showed  no  significant  difference  at  0.05  level
between pre vs. post test result.  The pre test mean was 2.74 & post test
mean 2.94  with mean difference only 0.2. This showed no significant
difference in  FEV1  level  between  pre  &  post  stress  level  of  control
group.
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 TABLE VII
FEV1
Liters / Sec
Mean
Mean
Diff.
SD
Un Paired
T – value
Post Test (Experimental Group) 3.13 0.19 0.09 5.93Post test (Control Group) 2.94
The unpaired “t” value 5.93 was greater than that of the tabulated
‘t’ value 2.05 which showed a significant difference at the level of 0.05
between post FEV1 of control & experimental group.
The  post  test  mean  of  control  group  being  2.94  &  that  of
experimental  group  being    3.13  with  mean  difference  of  1.19.  This
showed a significant  difference  in  FEV1 level  between post  test  score
between control & experimental group.
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DISCUSSION 
The  aim of  the  study  was  to  assess  the  effectiveness  of  flutter
mucus  clearance  device  on  Lung  function  in  COPD  subjects  with
Retained secretion.
TOOL SELECTION 
Tool  selection  was  based  on  the  study  of  HARISTARA  –
PAPADOPOULON, NORMAN WOLKOVE, Which is highly reliable.
STUDY SELECTION
Studier done by  SHARON M.H. et al., L.C. de. LIMAA et al.,
ANGSHU BROWMIKA et  al., supported the  present  study result  of
increased  pulmonary  function  and  mucus  removal  with  flutter  mucus
clearance device.
In the data analysis and interpretation using forced vital capacity
the post test value of controlled group was    2.75.   The post test value of
Experimental  group was 3.14,  which showed a significant  different  in
FVC levels between post test levels between controlled and Experimental
group of  0.39.
By using the Force expiratory volume in one second, the post test
mean  of  control  group  was  2.94  and  that  of  experimental  group  
was 3.13 with mean different being             .
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This  showed  a  significant  difference  in  FEV1  and  FVC  level
between post test scores between control and experimental groups.        
REASONS FOR IMPROVEMENT      
Norman wolkove 2010 found that flutter device produce a positive
expiratory pressure which is turn produces a vibrating movement is the
chest which looses the mucus and retained it out, thus improving the lung
function in COPD subjects.    
  
Hristara  papadopoulon  2003  determine  the  effectiveness  of
current  devices  of  respiratory  physiotherapy  as  an  alternative  method.
These mucus clearance devices, seem to increases patient’s compliance of
daily treatment, as an independent application, full control of therapy and
easy use, which helps removal of mucus from the airways and improves
quality of life of the patients and pulmonary function.    
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SUMMARY & CONCLUSION
SUMMARY
The  purpose  of  this  study  was  to  find  out  the  effect  of  Flutter
mucous clearance device on Lung function in CODD subjects.  The total
30 subjects of age group 40 to 60 years were diagnosed as bronchitis
(COPD) from GH and OP were randomly selected for this study and they
were taught to use flutter device for the period of 2 months.  Before and
after 2 months of training programme, the pre and post test values were
measured with computerized spirometer were recorded.  The paired t-test
was used to compare the difference between pre and post test value.
Based  on  the  statistical  analysis  the  result  of  the  study  showed
significant  improvement  in  increasing  Lung  function  by  using  flutter
Device.
CONCLUSION
As the incidence of stress and chronic illness increase the challenge
to the physiotherapist to treat Bronchitis (COPD) Patients.  Flutter device
increases the Lung function and reduce mucous retention.
This study concluded that there was a significant effect of flutter
Mucus  clearance  device  on  Lung  function  in  COPD  subjects  with
retained secretion.
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RECOMMENDATION
¾ Further  studies  can  be  conducted  with
positive end expiratory Pressure and High frequency chest
wall  oscillation  with  the  same  parameter  which  were
followed in this study.
¾ Further  studies  can  be  conducted  with
flutter  device  on  other  respiratory  conditions  such  as
Bronchiectasis, Cystic fibrosis, Asthma etc.,
¾ Further Studies can be done with flutter
device on Parameters like Sputum scale, dyspnoea scale etc.,
¾ Further studies may be done to compare
the flutter device and Acapella on COPD subjects.
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APPENDIX
TECHNIQUE
POSITION OF PATIENT 
The patient should be seated with back straight and head slightly
tilted upward so the upper airway is wide open.
As an alternative, the patient may be seated with elbows resting on
a  table  at  a  comfortable  level  and  head  positioned  as  slightly  tilted
upward.
TECHNIQUES
STAGE 1- MUCUS LOOSENING AND MUCUS MOBILIZATIONS
¾ Make the patient to relax assume proper posture and position.
¾ Ask the patient to slowly inhale beyond a normal breath, but do not
fill lungs completely.
¾ Now ask the patient to hold breath for 2 to 3 seconds.
¾ Now ask the patient to place the FLUTTER in Mouth, adjust tilt to
feel maximum of vibrations within chest, keep checks stiff.
¾ Now exhale through FLUTTER at a reasonably fast  but not too
forceful speed, using abdominal breathing.
¾ Exhale  beyond  a  normal  breath,  but  do  not  empty  lungs
completely.
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¾ Patient should Attempt to suppress cough.
¾ Make the patient to repeat stage 1 for 5 to 10 breaths.  
FIG:3-FLUTTER DEVICE WITH PATIENT
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STAGE 2 – MUCUS ELIMINATION
¾ Ask the patient to slowly inhale, filling lungs completely.
¾ Ask to hold the breath for 2 to 3 seconds.
¾ Now ask the patient to place FLUTTER in mouth, adjust tilt to
feel maximum of vibrations with in chest, keep cheeks stiff.
¾  Ask to exhale forcefully through FLUTTER as completely  as
possible.
¾ Make the patient to repeat stage 2 for 1 to 2 breaths.
¾ Now the patient should initiate cough (or “huff” maneuver) and
return to stage 1 and repeat full sequence (stage 1 and 2) until
lungs are clear or therapy is over.
Each Session ranging from 5-15 minutes per day 
TERMINATION
FLUTTER  therapy  is  complete  when  no  further  mucus  can  be
expectorated  following  several  diligent  sequences,  and  successful
clearing of the airways occur is approximately 5 to 15 minutes.
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INFORMED CONSENT FOR VOLUNTARY
PARTICIPATION IN A RESEARCH INVESTIGATION
Name :
Age : 
Sex :
Occupation :
Address for communication :
Declaration 
I  have  fully  understood  the  nature  and  purpose  of  the  study.  I
accept to be  a subject in this study. I declare that the above informed is
true  to my knowledge.
Date : 
Place :
Signature of the subject
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ASSESSMENT CHART
Name :
Age : 
Sex :
Side :
Mode of treatment : Flutter device
Measurement 
Parameter Before treatment After treatment
Forced vital capacity 
in litres
Forced expiratory  
volume per second
Signature of the investigator
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